GlassScriptPhysician profile
Deborah Simmons
NPI 1104367713
$7,375.30
in general payments reported to CMS, 2019-2025
17 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,477 · 2022: $2,449 · 2023: $1,553 · 2024: $534 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,250 · Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,250.00 |
| Food and Beverage | $1,199.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,136.84 | 2021-2025 | Fasenra, Tezspire |
| United Therapeutics Corporation | $769.93 | 2021-2022 | |
| Abbvie INC. | $101.85 | 2024-2025 | |
| Braeburn INC. | $48.80 | 2025 | Brixadi |
| Actelion Pharmaceuticals US, INC. | $39.27 | 2021 | |
| Indivior INC. | $35.07 | 2025 | Sublocade |
| Exact Sciences Corporation | $32.41 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $30.53 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $28.95 | 2025 | Pifeltro |
| Gilead Sciences, INC. | $25.15 | 2024 | Epclusa |
| Alkermes, INC. | $22.86 | 2024 | Vivitrol |
| Genzyme Corporation | $22.64 | 2021 | |
| Lilly USA, LLC | $20.83 | 2025 | Zepbound, Mounjaro |
| Insmed, INC. | $15.41 | 2021 | |
| Electromed, INC. | $15.01 | 2024 | Smartvest |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $14.96 | 2025 | Zenpep |
| Novo Nordisk INC | $14.79 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.